With several mega cap biopharma companies having their vital manufacturing steps in Chinese facilities, the novel coronavirus (Covid-19) outbreak is putting the complicated global biopharma industry’s supply chain under strain, says GlobalData, a leading data and analytics company.
Supply chain problems in China include a largely quarantined workforce, delays in transporting materials and several other logistical hurdles. While some Chinese factories have returned to normal capacity, others are reportedly operating at between 50% and 80% capacity.
As a result, the ongoing Covid-19 pandemic may affect drugs made and marketed by mega cap biopharma companies such as the UK-based AstraZeneca and Switzerland-based Novartis and Roche.
Fiona Barry, Associate Editor of PharmSource at GlobalData, says: “Restrictions on pharmaceutical manufacturing and export will affect many products sold in the US, EU, and other markets. Some of these drugs are manufactured in-house at the biopharma companies’ Chinese manufacturing sites—also known as ‘captive capacity’ manufacturing—while others are outsourced to contract manufacturing organizations (CMOs) with facilities in China.”
Affected drugs include AstraZeneca’s Plendil (felodipine), marketed for angina, whose finished dose form is manufactured in-house at AstraZeneca’s site in Wuxi, Jiangsu, China, and Pfizer’s antidepressant Zoloft (sertraline hydrochloride), whose dose form manufacture and packaging are performed at Pfizer’s site in Dalian, Liaoning, China.
However, this does not mean manufacture of these drugs is completely halted. Several biopharma companies dual-source their manufacturing. For instance, the dose form of AstraZeneca’s Plendil is also manufactured at the company’s Stockholm, Sweden site, and Zoloft is manufactured at several sites outside China by Pfizer and by CMOs.
“It is unclear to what extent disruption in China will affect the world’s supply of pharmaceuticals, as other regions are increasing their production. The Government of India has announced US$1.96bn boost to domestic active pharmaceutical ingredient manufacturing driven by the Covid-19 pandemic’s effect on Chinese supply chains,” says Barry.
Follow The Indian Sun to Twitter.
Support Independent Community Journalism
Dear Reader,The Indian Sun exists for one reason: to tell stories that might otherwise go unheard.
We report on local councils, state politics, small businesses and cultural festivals. We focus on the Indian diaspora and the wider multicultural community with care, balance and accountability. We publish in print and online, send regular newsletters and produce video content. We also run media training programs to help community organisations share their own stories.
We operate independently.
Community journalism does not have the backing of large media corporations. Advertising revenue fluctuates. Platform algorithms change. Costs continue to rise. Yet the need for credible, grounded reporting in a multicultural Australia has never been greater.
When you support The Indian Sun, you support:
• Independent reporting on issues affecting migrant communities
• Coverage of local and state decisions that shape daily life
• A platform for small businesses and community groups
• Media training that builds skills within the community
• Journalism accountable to readers
We cannot cover everything, but we work to cover what matters.
If you value thoughtful reporting that reflects Australia’s diversity, we invite you to contribute. Every donation helps us maintain the quality and consistency of our work.
Please consider making a contribution today.
Thank you for your support.
The Indian Sun Team
